Research map: Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs

Back to the article

Papers in this map

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update · Josef S Smolen · 2017 · 7417 citations · Cited by this paper
  2. Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study) · 2026 · Related
  3. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis · Steven R. Ytterberg · 2022 · 1819 citations · Cited by this paper
  4. Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic Arthritis · 2026 · Related
  5. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis · Annette H M van der Helm–van Mil · 2005 · 488 citations · Cited by this paper
  6. Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study · 2026 · Related
  7. The role of autoantibodies in the pathophysiology of rheumatoid arthritis · Veerle F. A. M. Derksen · 2017 · 327 citations · Cited by this paper
  8. Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials · 2025 · Related
  9. JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data · Robert D. Harrington · 2020 · 244 citations · Cited by this paper
  10. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies · 2026 · Related
  11. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future · Jacopo Angelini · 2020 · 228 citations · Cited by this paper
  12. Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials · 2025 · Related
  13. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance · Christina Charles‐Schoeman · 2022 · 219 citations · Cited by this paper
  14. Long-term Effectiveness and Safety of Canakinumab in Patients with TRAPS: Analysis of the RELIANCE Non-Interventional Study · 2025 · Related
  15. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology · Mikhail Volkov · 2019 · 201 citations · Cited by this paper
  16. Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe · 2025 · Related
  17. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort · James Bluett · 2014 · 107 citations · Cited by this paper
  18. Diuretic-Induced Hypomagnesemia May Play a Key Role in the Development of Calcium Pyrophosphate Arthritis · 2026 · Related
  19. Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis · Lin Li · 2017 · 77 citations · Cited by this paper
  20. Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials · 2025 · Related
  21. Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery · Disha Kesharwani · 2019 · 72 citations · Cited by this paper
  22. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry · D. Choquette · 2019 · 49 citations · Cited by this paper
  23. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters · Irazú Contreras-Yáñez · 2015 · 48 citations · Cited by this paper
  24. Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register · Giovanni Cagnotto · 2020 · 33 citations · Cited by this paper
  25. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors · Jeffrey Ian Weitz · 2022 · 29 citations · Cited by this paper
  26. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry · Leslie R. Harrold · 2019 · 28 citations · Cited by this paper
  27. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study · Kosuke Ebina · 2023 · 27 citations · Cited by this paper
  28. Real-world retention rates of biologics in patients with rheumatoid arthritis · Kenji Takami · 2023 · 9 citations · Cited by this paper
  29. THU0160 THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICAL EFFICACY AND SAFETY OF ABATACEPT IN SEROPOSITIVE, BIOLOGIC-NAÏVE PATIENTS WITH EARLY, MODERATE-TO-SEVERE RA TREATED WITH ABATACEPT OR ADALIMUMAB: DATA FROM THE OPEN-LABEL SWITCH PERIOD OF THE HEAD-TO-HEAD SINGLE-BLINDED ‘EARLY AMPLE’ TRIAL · William F. C. Rigby · 2020 · 1 citation · Cited by this paper
  30. Untitled · Cited by this paper

Source: OpenAlex (CC0)